Benitec Biopharma Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Benitec Biopharma Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jun 30, 2021 | $59.0K | Sep 20, 2021 |
| FY2021 | Jun 30, 2020 | $102.0K | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $12.20M | Sep 23, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($8.81M) | Mar 20, 2026 |
| FY2025 | Sep 30, 2024 | ($5.06M) | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | ($21.75M) | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | ($19.56M) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | ($18.21M) | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | ($13.88M) | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | ($8.27M) | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $2.61M | Sep 23, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($9.83M) | Mar 20, 2026 |
| FY2025 | Sep 30, 2024 | ($5.79M) | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | ($22.49M) | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | ($19.08M) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | ($17.85M) | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | ($13.60M) | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | ($8.28M) | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $2.58M | Sep 23, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.87M | Mar 20, 2026 |
| FY2025 | Sep 30, 2024 | $3.59M | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | $15.61M | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | $12.77M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $11.27M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $7.02M | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | $3.00M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $4.57M | Sep 23, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($23.59M) | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | ($19.40M) | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | ($18.01M) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | ($15.90M) | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | ($12.83M) | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | ($7.54M) | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $4.79M | Sep 23, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $18.0K | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | $179.0K | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | $1.0K | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $13.0K | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $221.0K | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | $95.0K | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $404.0K | Sep 23, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $99.59M | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | $52.21M | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | $4.46M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $5.97M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $21.38M | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | $11.59M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $19.24M | Sep 23, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.30M | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | $4.96M | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | $4.26M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $3.09M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $1.37M | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | $1.35M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | $2.64M | Sep 23, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $97.30M | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | $47.25M | Mar 20, 2026 |
| FY2025 | Jun 30, 2023 | $202.0K | Mar 20, 2026 |
| FY2024 | Jun 30, 2022 | $2.88M | Sep 26, 2024 |
| FY2023 | Jun 30, 2021 | $20.01M | Sep 21, 2023 |
| FY2022 | Jun 30, 2020 | $10.24M | Sep 2, 2022 |
| FY2021 | Jun 30, 2019 | $16.59M | Sep 20, 2021 |
| FY2020 | Jun 30, 2018 | $13.84M | Sep 23, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($228.18M) | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | ($190.26M) | Mar 20, 2026 |
| FY2024 | Mar 31, 2024 | ($185.54M) | Sep 26, 2024 |
| FY2024 | Dec 31, 2023 | ($181.26M) | Sep 26, 2024 |
| FY2024 | Sep 30, 2023 | ($174.46M) | Sep 26, 2024 |
| FY2024 | Jun 30, 2023 | ($167.89M) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | ($148.33M) | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | ($130.12M) | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | ($116.64M) | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | ($108.87M) | Sep 23, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $97.74M | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | $50.87M | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | $2.48M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $4.06M | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | $19.77M | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | $9.80M | Sep 20, 2021 |
| FY2021 | Jun 30, 2019 | $15.72M | Sep 20, 2021 |
| FY2020 | Jun 30, 2018 | $11.88M | Sep 23, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Mar 20, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | (1) | Mar 20, 2026 |
| FY2024 | Mar 31, 2024 | (7) | Sep 26, 2024 |
| FY2024 | Dec 31, 2023 | (5) | Sep 26, 2024 |
| FY2024 | Sep 30, 2023 | (3) | Sep 26, 2024 |
| FY2024 | Jun 30, 2023 | (14) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | (37) | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | (3) | Sep 2, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Mar 20, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | (1) | Mar 20, 2026 |
| FY2024 | Mar 31, 2024 | (7) | Sep 26, 2024 |
| FY2024 | Dec 31, 2023 | (5) | Sep 26, 2024 |
| FY2024 | Sep 30, 2023 | (3) | Sep 26, 2024 |
| FY2024 | Jun 30, 2023 | (14) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | (37) | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | (3) | Sep 2, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 26.25M | Mar 20, 2026 |
| FY2025 | Mar 31, 2025 | 25.55M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 23.45M | Mar 20, 2026 |
| FY2025 | Jun 30, 2024 | 10.09M | Mar 20, 2026 |
| FY2024 | Jun 30, 2023 | 1.67M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | 480,688 | Sep 21, 2023 |
| FY2022 | Jun 30, 2021 | 8.17M | Sep 2, 2022 |
| FY2021 | Jun 30, 2020 | 1.11M | Sep 20, 2021 |
| FY2020 | Jun 30, 2019 | 856,765 | Sep 23, 2020 |